The partnership combines Noom's
best-in-class content and coaching with Accolade's
advanced primary care physicians
SEATTLE, May 21, 2024
/PRNewswire/ -- Accolade, Inc. (Nasdaq: ACCD) announced today that
Noom has joined Accolade's Trusted Partner Ecosystem to provide
customers with a comprehensive solution for weight loss and
metabolic health, including support for GLP-1s and other
anti-obesity medications. In addition to the standard integrated
features that drive appropriate Trusted Partner utilization, Noom's
clinical obesity management solution, Noom Med, will be powered by
Accolade physicians extensively trained in weight loss protocols
and advanced primary care. The addition of Noom to Accolade's
partner ecosystem builds on Accolade's existing partnership in the
metabolic space with Virta Health.
Accolade and Noom's partnership offers employers a
comprehensive, evidence-based model with personalized offerings for
an employer's entire population, including connecting higher-risk
members with Accolade physicians. This partnership empowers
employers to stem the rising healthcare costs associated with
obesity and its many comorbid conditions – and to ensure
increasingly in-demand GLP-1s are appropriately prescribed and
those taking them supported clinically.
Noom leverages psychology and science to drive behavioral
change. Noom's enterprise solutions provide personalized, tailored
support for members' unique weight loss journeys. Through a
combination of informative content, nutrition, activity tracking
tools, coaching, and community, Noom has proven to help people
suffering from obesity lose at least 10% of their body weight and
keep it off - with 42% of users maintaining total weight loss for
at least two years. Noom's strong brand recognition consistently
generates on average an employee adoption rate of 25%, helping
drive meaningful results across an employer's population.
"In May 2023, responding to the
marked increase in anti-obesity medication adoption, Noom launched
Noom Med to provide high-quality clinical support to those
suffering from the chronic disease of obesity," said Noom's CEO,
Geoff Cook. "We put rigorous
clinical protocols and a sophisticated technology platform in place
to facilitate integration between physician-led care teams and our
valuable content and coaching. Accolade's proven track record in
primary care and building longitudinal relationships sets them
apart – we see them as an ideal partner with whom to grow
together."
When a member first engages with Noom, they'll complete a
personalized assessment determining whether they're best served by
(a) Noom Weight, a digital
psychology-based weight management program, (b) Noom Diabetes
Prevention Program, a tailored digital solution for those who show
risk of diabetes - awarded full plus recognition by the CDC, or (c)
Noom Med powered by Accolade, where Accolade physicians provide
evidence-based obesity care that augments Noom's digital support.
Non-GLP-1 anti-obesity medications are expected to be the initial
course of action for nearly half of all participants. For more on
the member experience, see here.
"When a member goes to Noom Med powered by Accolade, we
ensure that the right members are gaining access to GLP-1s or other
anti-obesity treatment and that members are making the behavior and
lifestyle changes necessary to, where appropriate, successfully
taper off those medications," said Dr. James Wantuck, Accolade Chief Medical Officer.
"Our customers and members will benefit from Accolade's
physician-led model combined with Noom's best-in-class content,
coaching, and community. This innovative combination will drive
sustainable weight-loss outcomes and reduce inappropriate
spending."
Obesity is a significant health and business challenge.
Nationwide obesity rates have more than tripled since the
1960s, with the current estimated rate at 43%. Obesity
is associated with a heightened risk of heart disease, type 2
diabetes, cancer, asthma, and other preventable health problems.
Estimates put the annual medical costs related to obesity in
the US at $173 billion, and employers
are contending with a dramatic uptick in GLP-1 utilization,
which has contributed to an 8.4% increase in pharmacy benefit
costs.
Accolade's Trusted Partner Ecosystem Increases Digital
Solution Engagement
Launched in 2019, Accolade's Trusted Partner Ecosystem
accelerates the performance of digital health solutions to improve
outcomes across valued categories for employers. Accolade's
ecosystem currently consists of 18 partners across 11
categories.
Benefits teams can confidently select from thoroughly vetted
solutions and enjoy streamlined contracting and implementation.
Through qualified referrals, Accolade drives more engagement with
partner solutions, leading to exponentially better health outcomes
and better value. Learn more here.
About Accolade
Accolade (Nasdaq: ACCD) is a Personalized Healthcare company
that provides millions of people and their families with
exceptional healthcare experiences so they can live their
healthiest lives. Accolade's employer, health plan, and consumer
solutions combine virtual primary care and mental health, expert
medical opinions, and best-in-class care navigation. These
offerings are built on a platform engineered to care through
predictive engagement of population health needs, proactive care
that improves outcomes and cost savings, and by addressing barriers
to access and continuity of care. Accolade consistently receives
consumer satisfaction ratings of over 90%. For more information,
visit accolade.com. Follow us
on LinkedIn, X, Instagram, and Facebook.
About Noom
Noom is the digital healthcare company empowering people to live
better, longer lives. Noom connects people to content, coaching,
community, and clinicians to improve whole-person health. Noom also
works with leading employers, health plans, and health systems,
offering Noom Med, Noom GLP-1 Companion, Noom Weight, Noom Diabetes Prevention Program,
and Noom Mood to millions of covered
lives. The company has been awarded multiple grants from the
National Institutes of Health and was the first mobile application
to be recognized by the Centers for Disease Control and Prevention
as a certified diabetes prevention program. With offices in
New York City and Princeton, New Jersey, Noom has been named one
of Inc.'s Best Places to Work, Quartz's Best Workplaces for Remote
Workers, and Fortune's Best Workplaces in Technology. To learn more
about Noom, visit noom.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/accolade-welcomes-noom-to-trusted-partner-ecosystem-302151148.html
SOURCE Accolade, Inc.